Revance Therapeutics CEO Mark Foley's 2021 pay slips 19% to $7.1M
Revance Therapeutics reports 2021 executive compensation
By ExecPay News
Published: March 24, 2022
Revance Therapeutics reported fiscal year 2021 executive compensation information on March 24, 2022.
In 2021, five executives at Revance Therapeutics received on average a compensation package of $3.7M, a 22% decrease compared to previous year.
Average pay of disclosed executives at Revance Therapeutics
Mark J. Foley, Chief Executive Officer, received $7.1M in total, which decreased by 19% compared to 2020. 64% of Foley's compensation, or $4.6M, was in stock awards. Foley also received $426K in non-equity incentive plan, $1.1M in option awards, $660K in salary, as well as $317K in other compensation.
For fiscal year 2021, the median employee pay was $248,326 at Revance Therapeutics. Therefore, the ratio of Mark J. Foley's pay to the median employee pay was 29 to one.
Dustin Sjuts, President, received a compensation package of $3.2M, which is about the same as previous year. 55% of the compensation package, or $1.8M, was in stock awards.
Aubrey Rankin, Former President, Innovation & Technology, earned $3M in 2021.
Abhay Joshi, Chief Operating Officer, received $2.6M in 2021, which decreases by 36% compared to 2020.
Tobin C. Schilke, Chief Financial Officer, earned $2.5M in 2021, a 15% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on March 24, 2022.